Examination of Witness

Part of Health Service Medical Supplies (Costs) Bill – in a Public Bill Committee at 10:30 am on 8 November 2016.

Alert me about debates like this

David Watson:

Again, I agree with that, and I understand quite often that medicines are repurposed, not necessarily by pharmaceutical companies, but by other research centres. Quite often, even in that scenario, those companies may expect a reasonable return on their effort to bring that product in, which might mean a price rise. Again, I would say that there has to be a balance between price rises to reward innovation and return on investment and those price rises that are clearly not justified.